Local low-dose IL-2 therapy.
Interleukin-2 (IL-2) is a powerful drug for treating cancer. However, it is only powerful if it is properly applied. That is, IL-2 should be applied at the tumor site, because at the transition of normal and malignant tissue are the tumor infiltrating cells. These should be activated by IL-2. Local application implies that IL-2 can be used in relatively low doses. It is becoming clear that even a single injection of IL-2 can cure cancer. IL-2 can also enhance the therapeutic effects of irradiation and Cisplatin. Locally applied IL-2 therapy is virtually non-toxic.
Den Otter
W
W
Department of Cell Biology, Utrecht University, The Netherlands. w.denotter@pobox.accu.uu.nl
Balemans
L
L
Battermann
J J
JJ
Bernsen
M R
MR
Cadee
J A
JA
Dobrowolski
Z
Z
Everse
L A
LA
Fiszer-Maliszewska
L
L
Gavhumende
R
R
De Groot
J W
JW
De Groot
K
K
Hennink
W E
WE
Hill
F W
FW
Jurgenliemp-Schulz
I
I
Klein
W R
WR
Koten
J W
JW
Maas
R A
RA
Steerenberg
P
P
Stewart
R
R
Zembala
M
M
D000818:Animals; D002294:Carcinoma, Squamous Cell / Q000628:therapy; D002417:Cattle; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005134:Eye Neoplasms / Q000628:therapy; D006801:Humans; D015552:Injections, Intralesional; D007376:Interleukin-2 / Q000008:administration & dosage*; D008223:Lymphoma / Q000628:therapy; D008325:Mammary Neoplasms, Experimental / Q000628:therapy; D012515:Mast-Cell Sarcoma / Q000628:therapy; D051379:Mice; D008811:Mice, Inbred DBA; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000628:therapy*; D013997:Time Factors; D014407:Tumor Cells, Cultured; D001749:Urinary Bladder Neoplasms / Q000628:therapy
D007376:Interleukin-2; D002945:Cisplatin